文献速递免疫规划卫生政策与健康促进

蒙古国轮状病毒疫苗接种的预期影响、成本效果与预算影响

Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia.
PubMed 文献 · Vaccine · 2019-01-11

本研究评估蒙古国全国婴儿轮状病毒疫苗接种的影响、成本效果与预算影响,比较两种剂次疫苗与不接种,采用模型分析十年期。结果显示接种可避免大量病例和死亡,具有高度成本效果,ROTAVAC®为最经济选择。

要点

  • 接种可避免超过95,000例轮状病毒病例和271例死亡。
  • 政府视角ICER为412至1050美元/DALY,社会视角为77至715美元/DALY。
  • 疫苗价格是主要不确定性因素,ROTAVAC®最经济。

核心结论

  • 蒙古国引入轮状病毒疫苗接种可能具有高度成本效果,ICER估计仅为蒙古国人均GDP的一小部分。
  • 从经济角度看,ROTAVAC®是成本最低且最具成本效果的产品选择。

研究设计与样本

  • 研究使用基于当地数据和已发表文献的模型方法,分析从2019年开始的十年期内轮状病毒疫苗接种的影响和成本效果,使用3%贴现率。
  • 分析比较两剂疫苗ROTARIX®和三剂疫苗ROTAVAC®、RotaTeq®与不接种,从政府和社会视角进行。
  • 主要结局指标为增量成本效果比(ICER),表示为每避免一个DALY的美元成本。

主要发现

  • 蒙古国轮状病毒疫苗接种可在十年内避免超过95,000例轮状病毒病例和271例死亡。
  • 从政府视角,ICER范围为412至1050美元;从社会视角,ICER范围为77至715美元。
  • 敏感性分析强调疫苗价格是不确定性的主要驱动因素。

临床怎么用

  • 决策者可参考成本效果结果支持轮状病毒疫苗引入,优先考虑ROTAVAC®作为经济选择。
  • 需关注疫苗价格对项目成本效果的影响。

局限性

  • 研究基于模型和假设,不确定性主要来自疫苗价格。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Rotavirus disease in Mongolia is estimated to cause more than 50 deaths yearly and many more cases and hospitalizations. Mongolia must self-finance new vaccines and does not automatically access Gavi prices for vaccines. Given the country's limited resources for health, it is critical to assess potential new vaccine programs. This evaluation estimates the impact, cost-effectiveness, and budget implications associated with a nationwide rotavirus vaccine introduction targeting infants as part of the national immunization program in Mongolia, in order to inform decision-making around introduction. METHODS: The analysis examines the use of the two-dose vaccine ROTARIX®, and three-dose vaccines ROTAVAC® and RotaTeq® compared to no vaccination from the government and the societal perspective. We use a modelling approach informed by local data and published literature to analyze the impact and cost-effectiveness of rotavirus vaccination over a ten-year time period starting in 2019, using a 3% discount rate. Our main outcome measure is the incremental cost-effectiveness ratio (ICER) expressed as US dollar per DALY averted. We assessed uncertainty around a series of parameters through univariate sensitivity analysis. RESULTS: Rotavirus vaccination in Mongolia could avert more than 95,000 rotavirus cases and 271 deaths, over 10 years. Averted visits and hospitalizations represent US$2.4 million in health care costs saved by the government. The vaccination program cost ranges from $6 to $11 million depending on vaccine choice. From the governmental perspective, ICER ranged from $412 to $1050 and from $77 to $715 when considering the societal perspective. Sensitivity analysis highlights vaccine price as the main driver of uncertainty. CONCLUSION: Introduction of rotavirus vaccination is likely to be highly cost-effective in Mongolia, with ICERs estimated at only a fraction of Mongolia's per capita GDP. From an economic standpoint, ROTAVAC® is the least costly and most cost-effective product choice.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lusvan ME, Debellut F, Clark A, et al. Projected impact, cost-effectiveness, and budget implications of rotavirus vaccination in Mongolia. Vaccine. 2019. PMID: 30639458. doi:10.1016/j.vaccine.2018.12.056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。